ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2319

Investigating the Association of Serum Metabolites with Psoriatic Arthritis Musculoskeletal Disease Patterns

Sheng Han Li1, Nikita Looby2, Max Kotiyar3, Lihi Eder4, Igor Jurisica5, Vathany Kulasingam6 and vinod Chandran7, 1Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada, 2Psoriatic Arthritis Program Schroeder Arthritis Institute, Toronto, Canada, 3Data Science Discovery Centre for Chronic Dsiease, Krembil Research Institute, Toronto, Canada, 4University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, 5Data Science Discovery Centre, Krembil Research Institute, Toronto, Canada, 6Laboratory Medicine Program, Unviersity Health Network, Toronto, Canada, 7Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: metabolomics, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Accurate assessment of disease patterns may be important for appropriate management of psoriatic arthritis (PsA). Ultrasonography (USG) is a highly accurate, sensitive, and non-invasive tool for disease activity assessment and determining the musculoskeletal (MSK) disease pattern of patients with PsA. Detailed USG of peripheral MSK structures is not feasible in routine practice. A metabolomics-based approach may elucidate potential biomarkers associated with USG-determined PsA patterns. Therefore, we aimed to use solid phase microextraction (SPME) with liquid chromatography coupled with mass spectrometry (LC-MS) to explore metabolome differences among PsA patients according to their USG-based patterns.

Methods: PsA patients were assessed and assigned corresponding domain scores for synovitis, enthesitis, peritenonitis, and tenosynovitis determined by USG of the MSK system. Hierarchical clustering was performed to determine USG-based patterns based on these domains. Serum samples collected at the time of USG scans were prepared using SPME, and the resulting extracts were used for analysis via LC-MS. Machine Learning (ML) models were used to evaluate associations between metabolite levels and MSK disease patterns. Model performances were summarized using Area under Receiver Operator Characteristic curves (AUROC). Models with predictive performance greater than 0.7 were considered, and potential metabolite candidates were tentatively identified.

Results:  76 patients (37 females) with mean age of 47.4 years (standard deviation (SD) 14.5), and mean PsA and psoriasis duration of 6.5 (SD 11.6) and 16.6 (SD 12.7) years respectively were recruited. The patients had a mean active (tender or swollen) joint count of 7.6 (SD 6.2) and swollen joint count of 4.4 (SD 4.0). 38.2% had dactylitis, and 63.2% had clinical enthesitis. Hierarchical clustering based on the USG data identified 3 different USG-based patterns (Figure 1): Cluster 1 (n=27) exhibited diffuse inflammation; Cluster 2 (n=6) lacked enthesitis; and Cluster 3 (n=43) had predominant synovitis. ML models were able to distinguish between USG-based patterns. The best performing models were- a LogitBoost model with 20 features (AUC of 0.986 between cluster 2 and 3), a NaïveBayes model with 40 features (AUC of 0.88 between cluster 1 and 3), and a NaïveBayes model with 5 features (AUC of 0.944 between cluster 1 and 2) (Figure 2). The features used in best performing models were associated with dysregulation of fatty acid metabolism. Tentatively identified metabolites include sphingomyelin (d18:0/16:0) which belongs to the sphingolipid class implicated in PsA skin lesions and are precursors to ceramides that can modulate the immune response. Other tentatively identified features belong to compound classes, phospholipids, diglycerides, and long-chain fatty acids (Tables 1-3).

Conclusion: An untargeted serum metabolomics approach found several fatty acid and lipid class metabolites associated with USG-based MSK disease patterns. A closer examination and validation of the circulating metabolites to reveal potential biomarkers associated PsA disease patterns and disease activity is underway. 

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: S. Li: None; N. Looby: None; M. Kotiyar: None; L. Eder: AbbVie, 2, 5, 6, Bristol-Myers Squibb (BMS), 2, Eli Lilly, 2, 5, Fresenius Kabi, 5, Johnson & Johnson, 2, 5, Novartis, 1, 5, Pfizer, 5, 6, UCB, 5, 6; I. Jurisica: None; V. Kulasingam: None; v. Chandran: None.

To cite this abstract in AMA style:

Li S, Looby N, Kotiyar M, Eder L, Jurisica I, Kulasingam V, Chandran v. Investigating the Association of Serum Metabolites with Psoriatic Arthritis Musculoskeletal Disease Patterns [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/investigating-the-association-of-serum-metabolites-with-psoriatic-arthritis-musculoskeletal-disease-patterns/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigating-the-association-of-serum-metabolites-with-psoriatic-arthritis-musculoskeletal-disease-patterns/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology